## Virginia Medicaid Preferred Drug List (PDL) Program: Review of New Drugs Pharmacy and Therapeutics Committee Meeting Monday, June 26, 2006 9:00 a.m., DMAS Board Room DRAFT AGENDA

Welcome and Comments from DMAS'

**Director** 

**Patrick Finnerty, DMAS Director** 

Comments from the

**Secretary of Health and Human Resources** 

The Honorable Marilyn Tavenner

**Secretary of Health and Human Resources** 

**Comments from the Chairperson** 

Randy Axelrod, M.D., Chairman

Acceptance of Minutes From March 30, 2006 P&T Meeting

**P&T** Committee Members

**Drug Class Discussions** 

**P&T** Committee Members

## Review of New Drugs in PDL Phase I

• Fluticasone – Nasal Corticosteroid

• Pravastatin – Lipotropics

Confidential Meeting Confidential Meeting for

P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to

discuss pricing information

Criteria Discussion of New Drugs\*

**P&T Committee Members** 

**Next Meeting** 

Randy Axelrod, M.D., Chairman

\*Criteria discussions will be held for drugs only if deemed PDL eligible by the P&T Committee during Drug Class Discussions